Journals / Türk Kardiyoloji Derneği Arşivi / 2002 / Cilt: 30 - Sayı: 10

Efficacy and safety of low molecular weight heparins in preventing thromboembolic events after cardioversion of atrial fibrillation

Atriyal fibrilasyonda kardiyoversiyon sonrası tromboembolik olayların önlenmesinde düşük molekül ağırlıklı heparinlerin etkinliği ve güvenliliği

Pages
621–626
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: TEE guided early CV in conjunction with short-term LMWH treatment is as safe as UFH for the prevention of the thromboembolic events after CV.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Transesophageal echocardiography (TEE) guided early cardioversion (CV) in conjunction with short-term anticoagulation has been shown to be safe, and an alternative to prolonged conventional anticoagulation therapy.
📊
Key Findings & Data:Methods and results: The study group consisted of 172 consecutive patients with NVAF.
💡
Conclusion & Impact:Conclusion: TEE guided early CV in conjunction with short-term LMWH treatment is as safe as UFH for the prevention of the thromboembolic events after CV.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: Transesophageal echocardiography (TEE) guided early cardioversion (CV) in conjunction with short-term anticoagulation has been shown to be safe, and an alternative to prolonged conventional anticoagulation therapy. Recently, low molecular weight heparins (LMWHs) have been used successfully as an alternative to standart heparin therapy obviating the need for hospitalization and APTT monitoring. The aim of this study was to determine the efficacy and safety of TEE guided early cardioversion in conjunction with short-term LMWH use in patients with nonvalvular atrial fibrillation (NVAF). Methods and results: The study group consisted of 172 consecutive patients with NVAF. Before TEE, 90 patients received LMWH (Dalteparin 2x5.000u SC) and 82 patients received standart heparin (UFH) (5.000u IV bolus followed by IV infusion to raise APTT to 1.5 times control). TEE was performed and left atrium and left atrial appendix was searched thoroughly for the presence of thrombus. One patients from each group was excluded due to detection of left atrial thrombus by TEE. Immediately after TEE, CV was attempted and warfarin was initiated. All patients received warfarin for one month after CV. In the LMWH group, 89 of 88 patients (98.9%) was successfully cardioverted. CV was successful in patients 97.5% in the UFH group. None of the patients experienced thromboembolic events during the four weeks after CV. Conclusion: TEE guided early CV in conjunction with short-term LMWH treatment is as safe as UFH for the prevention of the thromboembolic events after CV.

Özet

Amaç: Transözefagiyal ekokardiyografi (TÖE) rehberliğinde kısa süreli antikoagülasyonla erken kardiyoversiyonun güvenilir olduğu ve uzun süreli konvansiyonel antikoagülan tedaviye alternatif olduğu gösterilmiştir. Son zamanlarda, düşük molekül ağırlıklı heparin (DMAH)'ler hastanede yatmayı ve APTT kontrolu gerektirmemesi nedeniyle standart heparin tedavisine alternatif olarak kullanılmaktadır. Çalışmamızın amacı valvüler olmayan atriyal fibrilasyon (VOAF)'lu hastalarda TÖE rehberliğinde DMAH kullanılarak yapılan kısa süreli antikoagülan tedavi ile erken kardiyoversiyonun güvenliliğini saptamaktı. Materyel-Metod ve Bulgular: Çalışmaya VOAF'lu 172 ardışık hasta alındı. TÖE öncesi 90 hastaya DMAH (Dalteparin 2x5.000 ü) ve 82 hastaya standart heparin (5.000 ü bolusu takiben APTT kontrol değerinin 1.5 katına ulaşıncaya kadar infüzyon) verildi. TÖE ile sol atriyum ve sol atriyum apendiksinde trombus varlığı araştırıldı. Her iki gruptan da birer hasta, trombus saptanması nedeniyle çalışmadan çıkarıldı. TÖE'den hemen sonra kardiyoversiyon yapıldı ve hastalara varfarin başlandı. Hastaların tümü kardiyoversiyon sonrası bir ay süre ile varfarin kullandılar. DMAH grubunda 89 hastadan 88'inde (%98.9), standart heparin grubunda ise olguların %97.5'unda kardiyoversiyon başarılı oldu. Hastaların hiç birinde kardiyoversiyon sonrasındaki 4 hafta içinde tromboembolik olay gelişmedi. Sonuç: TÖE rehberliğinde kısa süreli DMAH tedavisi ile erken kardiyoversiyon, standart heparin kadar kardiyoversiyon sonrasında gelişebilecek tromboembolik olayların önlenmesinde güvenilirdir.

🔖

Cite This Article

YİĞİT, Z., ÖKÇÜN, B., KÜÇÜKOĞLU, M. S., SANSOY, V., MUTLU, H., GÜZELSOY, D. (2022). Efficacy and safety of low molecular weight heparins in preventing thromboembolic events after cardioversion of atrial fibrillation. Türk Kardiyoloji Derneği Arşivi, Cilt: 30 - Sayı: 10, 621–626. https://ajindex.com/articles/633956

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Lip GHY: Paroxysmal atrial fibrillation. In: (ed).: Lip GHY. Atrial Fibrillation in Clinical Practice. First edition, Martin Dunitz Ltd, London, United Kingdom, 2001. p: 137-47 2. Bjerkelund CJ, Orning OM: The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation. Am J Cardiol 1969
  2. 16 3. Laupacis A, Alberts G, Dunn M, Feinberg W: Antithrombotic therapy in atrial fibrillation. Chest 1992
  3. 31 4. Manning WJ, Silverman DI, Gordon SPE, Krumholz HM, Douglas PS: Cardioversion from atrial fibrillation without prolonged anticoagulation with use of transesophageal echocardiography to exclude the presence of atrial thrombi. N Engl J Med 1993
  4. 5 5. Black IW, Fatkin D, Sagar KB et al: Exclusion of atrial thrombus by transesophageal echocardiography does not preclude embolism after cardioversion of atrial fibrillation: A multicenter study. Circulation 1994
  5. 13 6. Grimm RA, Stewart WJ, Maloney JD et al: Impact of electrical cardioversion for atrial fibrillation on left atrial appendage function and spontaneous echo contrast: characterization by simultaneous transesophageal echocardiography. J Am Coll Cardiol 1993
  6. 66 7. Levy S, Breithardt G, Campbell RWF et al: Atrial fibrillation: current knowledge and recommendations for management (Working Group Report). Eur Heart J 1998
  7. 1320 8. Klein AL, Grimm RA, Black IW et al: Cardioversion guided by transesophageal echocardiography: the ACUTE Pilot Study - a randomized, controlled trial. Assessment of cardioversion using transesophageal echocardiography. Ann Intern Med 1997
  8. 9 9. Klein AL, Grimm RA, Murray DOR et al: Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 2001
  9. 20 10. Hirsh J, Levine MN: Low molecular weight heparin. Blood 1992
  10. 17 11. Warkentin TE, Levine MN, Hirsh J et al: Heparin-induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin. N Engl J Med 1995
  11. 5 12. Weitz JI: Low-molecular weight heparins. N Engl J Med 1997
  12. 98 13. Hyers TM, Agnelli G, Hull RD et al: Antithrombotic therapy for venous thromboembolic disease. Chest 1998
  13. 516S-578S 14. Leizorovicz A, Simonneau G, Decousus H, Boissel JP: Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparins in initial treatment of deep venous thrombosis: a meta-analysis. BJM 199